Results 121 to 130 of about 28,427 (257)

New‐Onset Type 2 Diabetes Mellitus and Cancer Risk: A Matched Cohort Study in China Kadoorie Biobank

International Journal of Cancer, EarlyView.
ABSTRACT The prevalence of type 2 diabetes mellitus (T2DM) is rising rapidly in China and is linked to increased cancer risk, but causality remains unclear due to biases. We examined the causal effect of T2DM on cancer risk using bias‐minimizing methods.
Mengying Wang, Owen Tipping, Bowen Liu, Derrick A. Bennett, Baiyong Shen, Siyi Zou, Shulin Zhao, Richard M. Martin, Matthew Sperrin, Andrew G. Renehan   +9 more
wiley   +1 more source

IRAS observations of NGC 1052 [PDF]

, 1984
The galaxy NGC 1052 has been observed with the IRAS satellite. The infrared emission at 100 microns is substantially larger than a smooth extrapolation of the radio data. Because of the large diaphragm size of IRAS, it is impossible to decide uniquely if
Rowan-Robinson, M., Rice, W., Neugebauer, G., Soifer, B. T.   +3 more
core  

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

The IRAS Minor Planet Survey [PDF]

, 1992
This report documents the program and data used to identify known asteroids observed by the Infrared Astronomical Satellite (IRAS) and to compute albedos and diameters from their IRAS fluxes. It also presents listings of the results obtained.
Fowler, John W., Veeder, Glenn J., Tedesco, Edward F., Chillemi, Joseph R.   +3 more
core  

Diabetes Increases Immunotherapy‐Related Toxicity but Not Efficacy in Metastatic Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study

International Journal of Cancer, EarlyView.
ABSTRACT This multicenter retrospective study evaluated the impact of type 2 diabetes mellitus (DM) on clinical outcomes and immune‐related adverse events (irAEs) in 450 patients with metastatic non‐small cell lung cancer (NSCLC) treated with second‐line nivolumab at 17 centers between 2016 and 2024. Among these patients, 118 (26.2%) had DM.
Emre Çakır, Didem Divriklioğlu, Deniz Can Güven, Gamze Serin Özel, Oğuzhan Yıldız, Gamze Emin, Merve Keskinkılıç, Yeşim Ağyol, Onur Yazdan Balçık, Nagihan Kolkıran, Hale Gülçin Yıldırım Doğan, Pervin Can Şancı, Özge Yalıcı, Teoman Şakalar, Yurdagül Danacı, Yakup Düzköprü, Canan Yıldız, Mesut Yılmaz, İlhan Hacıbekiroğlu, Bülent Erdoğan, Saadettin Kılıçkap, Gamze Gököz Doğu, Melek Karakurt Eryılmaz, Atila Yıldırım, İlhan Öztop, İbrahim Vedat Bayoğlu, Şahnura Uzuntaş, Atike Pınar Erdoğan, Emir Çelik, Devrim Çabuk, Erdoğan Selçuk Şeber, Zehra Sadak Öcal, Hacer Demir   +32 more
wiley   +1 more source

Incidence and Predictors of Immune‐Related Hypothyroidism Under Pembrolizumab Across Gynecologic Malignancies and Melanoma: A Real‐World Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) frequently cause thyroid immune‐related adverse events (irAEs). Permanent hypothyroidism, the clinically most relevant phenotype, requires lifelong hormone replacement. We investigated its incidence, course, risk factors, and prognostic relevance under pembrolizumab.
Freya Koffka, Johann Kornowski, Elena Laakmann, Barbara Schmalfeldt, Tim Zell, Glenn Geidel, Christoffer Gebhardt, Pia Roser, Volkmar Müller, Julian Kött   +9 more
wiley   +1 more source

A Primer On IRAs

Individual Retirement Accounts (IRAs) now hold more assets than either defined benefit or defined contribution pension plans, but many people do not understand how they work.
Alicia H. Munnell
core  

Early Cessation of Adjuvant Anti‐PD‐1 Therapy in Stage III and IV Melanoma

International Journal of Cancer, EarlyView.
ABSTRACT One year of adjuvant anti‐PD‐1 has improved disease‐free survival in Stage III melanoma. It is unknown whether shorter treatment duration affects outcomes. Real‐world data may help clarify this. In this retrospective observational study, patients with resected Stage III/IV melanoma receiving adjuvant anti‐PD‐1 in the Netherlands from 2018 to ...
Manja Bloem, Melissa M. de Meza, Cato D. M. Boreel, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Willeke A. M. Blokx, Marye J. Boers‐Sonderen, Han J. Bonenkamp, Jan Willem B. de Groot, John B. Haanen, Geke A. P. Hospers, Ellen Kapiteijn, Djura Piersma, Bart Rikhof, Lieke H. J. Simkens, Marion A. Stevense‐den Boer, Astrid A. M. van der Veldt, Karijn P. M. Suijkerbuijk, Alfonsus J. M. van den Eertwegh, Michel W. J. M. Wouters   +20 more
wiley   +1 more source

Monitoring van luchtkwaliteit in een veehouderijrijke omgeving in de provincie Limburg : inzicht in verschillen en overeenkomsten tussen componenten: Rapportage van metingen op meerdere lokaties [PDF]

, 2020
Hoek, G., Scherpenisse, P., van Schothorst, I.J., Spithoven, J.J.G., Heederik, D.J.J., Wouters, I.M.   +5 more
core  

Cysteine Peptidases in Antitumor Immunity: Unraveling Antigen‐Presenting Cell Regulation and Therapeutic Potential

iMetaMed, EarlyView.
This review systematically summarizes the central role of cysteine peptidases in modulating antigen‐presenting cell (APC) function and antitumor immune responses, highlighting their critical significance in overcoming tumor immune evasion. Current research has established that cysteine peptidase subtypes, including cathepsins B, S, L, and X, exert ...
Yimao Wu, Xiaoyan Chen, Zichang Chen, Yalun Liang, Gokhan Zengin, Qian Zhang, Wenlong Sun, Meng‐Yao Li   +7 more
wiley   +1 more source